covid_vs_flu: update O’Driscoll (now published in Nature)

This commit is contained in:
Marc Bevand
2020-11-22 13:51:52 -08:00
parent fb929069ac
commit 821b6eeb18
3 changed files with 25 additions and 23 deletions
+1 -1
View File
@@ -34,7 +34,7 @@ The COVID-19 IFR curves represent these estimates:
1. [Gudbjartsson et al.: Humoral Immune Response to SARS-CoV-2 in Iceland](https://www.nejm.org/doi/full/10.1056/NEJMoa2026116), 1. [Gudbjartsson et al.: Humoral Immune Response to SARS-CoV-2 in Iceland](https://www.nejm.org/doi/full/10.1056/NEJMoa2026116),
specifically [Supplementary Appendix 1](https://www.nejm.org/doi/suppl/10.1056/NEJMoa2026116/suppl_file/nejmoa2026116_appendix_1.pdf) (table S7) specifically [Supplementary Appendix 1](https://www.nejm.org/doi/suppl/10.1056/NEJMoa2026116/suppl_file/nejmoa2026116_appendix_1.pdf) (table S7)
1. [PHAS - Public Health Agency of Sweden: The infection fatality rate of COVID-19 in Stockholm Technical report](https://www.folkhalsomyndigheten.se/contentassets/53c0dc391be54f5d959ead9131edb771/infection-fatality-rate-covid-19-stockholm-technical-report.pdf) (table B.1) 1. [PHAS - Public Health Agency of Sweden: The infection fatality rate of COVID-19 in Stockholm Technical report](https://www.folkhalsomyndigheten.se/contentassets/53c0dc391be54f5d959ead9131edb771/infection-fatality-rate-covid-19-stockholm-technical-report.pdf) (table B.1)
1. [ODriscoll et al.: Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries](https://www.medrxiv.org/content/10.1101/2020.08.24.20180851v1) (table S4) 1. [ODriscoll et al.: Age-specific mortality and immunity patterns of SARS-CoV-2](https://www.nature.com/articles/s41586-020-2918-0) (table S3)
1. [Ward et al.: Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults](https://www.medrxiv.org/content/10.1101/2020.08.12.20173690v2), 1. [Ward et al.: Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults](https://www.medrxiv.org/content/10.1101/2020.08.12.20173690v2),
specifically [Supplementary Appendix](https://www.medrxiv.org/highwire/filestream/93745/field_highwire_adjunct_files/0/2020.08.12.20173690-1.docx) (table S2a, column "Based on confirmed COVID-19 deaths") specifically [Supplementary Appendix](https://www.medrxiv.org/highwire/filestream/93745/field_highwire_adjunct_files/0/2020.08.12.20173690-1.docx) (table S2a, column "Based on confirmed COVID-19 deaths")
1. [Yang et al.: Estimating the infection fatality risk of COVID-19 in New York City during the spring 2020 pandemic wave](https://www.medrxiv.org/content/10.1101/2020.06.27.20141689v2) (table 1) 1. [Yang et al.: Estimating the infection fatality risk of COVID-19 in New York City during the spring 2020 pandemic wave](https://www.medrxiv.org/content/10.1101/2020.06.27.20141689v2) (table 1)
BIN
View File
Binary file not shown.

Before

Width:  |  Height:  |  Size: 588 KiB

After

Width:  |  Height:  |  Size: 570 KiB

+24 -22
View File
@@ -137,27 +137,29 @@ ifrs_covid = [
(90,maxage): 16.21, (90,maxage): 16.21,
}), }),
# ODriscoll et al.: Age-specific mortality and immunity patterns of SARS-CoV-2 infection in 45 countries # ODriscoll et al.: Age-specific mortality and immunity patterns of SARS-CoV-2
# https://www.medrxiv.org/content/10.1101/2020.08.24.20180851v1 # https://www.nature.com/articles/s41586-020-2918-0
# (table S4) # Supplementary information
# https://static-content.springer.com/esm/art%3A10.1038%2Fs41586-020-2918-0/MediaObjects/41586_2020_2918_MOESM1_ESM.pdf
# (table S3)
('ODriscoll', { ('ODriscoll', {
(0,4): 0.002, (0,4): 0.003,
(5,9): 0, (5,9): 0.001,
(10,14): 0, (10,14): 0.001,
(15,19): 0.002, (15,19): 0.003,
(20,24): 0.004, (20,24): 0.006,
(25,29): 0.009, (25,29): 0.013,
(30,34): 0.017, (30,34): 0.024,
(35,39): 0.029, (35,39): 0.040,
(40,44): 0.053, (40,44): 0.075,
(45,49): 0.086, (45,49): 0.121,
(50,54): 0.154, (50,54): 0.207,
(55,59): 0.241, (55,59): 0.323,
(60,64): 0.359, (60,64): 0.456,
(65,69): 0.642, (65,69): 1.075,
(70,74): 1.076, (70,74): 1.674,
(75,79): 2.276, (75,79): 3.203,
(80,maxage): 7.274, (80,maxage): 8.292,
}), }),
# Ward et al.: Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults # Ward et al.: Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults
@@ -388,8 +390,8 @@ def main():
fig.suptitle('Infection Fatality Ratio of COVID-19 vs. Seasonal Influenza') fig.suptitle('Infection Fatality Ratio of COVID-19 vs. Seasonal Influenza')
ax.text(0, -0.11, ax.text(0, -0.11,
'Source: https://github.com/mbevand/covid19-age-stratified-ifr\n' 'Source: https://github.com/mbevand/covid19-age-stratified-ifr\n'
'Note: the vertical lines on two COVID-19 IFR curves (Poletti and ODriscoll) are caused by the IFR being\n' 'Note: the vertical lines on one COVID-19 IFR curve (Poletti) are caused by the IFR being\n'
'estimated to be zero by Poletti for age groups 0-19 and 20-49, and by ODriscoll for 5-9 and 10-14.\n', 'estimated to be zero for age groups 0-19 and 20-49.\n',
transform=ax.transAxes, fontsize='small', verticalalignment='top', transform=ax.transAxes, fontsize='small', verticalalignment='top',
) )
ax.text(1, 1, 'Created by: Marc Bevand — @zorinaq', ax.text(1, 1, 'Created by: Marc Bevand — @zorinaq',